EKF Diagnostics (LON:EKF) Shares Up 27.3% – Still a Buy?

EKF Diagnostics Holdings plc (LON:EKF)’s stock price shot up 27.3% on Thursday . The company traded as high as GBX 26.90 ($0.36) and last traded at GBX 25.20 ($0.33). 2,253,335 shares traded hands during trading, an increase of 353% from the average session volume of 497,132 shares. The stock had previously closed at GBX 19.80 ($0.26).

EKF Diagnostics Trading Down 1.6%

The company has a current ratio of 4.60, a quick ratio of 1.77 and a debt-to-equity ratio of 0.34. The firm has a market cap of £110.25 million, a P/E ratio of 23.08 and a beta of 0.57. The business’s 50-day moving average is GBX 21.11 and its two-hundred day moving average is GBX 23.93.

EKF Diagnostics (LON:EKF) last issued its quarterly earnings data on Tuesday, March 25th. The company reported GBX 1.38 ($0.02) earnings per share (EPS) for the quarter. EKF Diagnostics had a return on equity of 7.03% and a net margin of 9.37%. As a group, analysts expect that EKF Diagnostics Holdings plc will post 2.2987842 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Gavin T. Jones purchased 50,000 shares of the company’s stock in a transaction on Tuesday, March 25th. The shares were bought at an average cost of GBX 22 ($0.29) per share, for a total transaction of £11,000 ($14,592.73). 5.24% of the stock is currently owned by insiders.

EKF Diagnostics Company Profile

EKF is an AIM-listed global diagnostics business focussed on:

● Point-of-Care analysers in the key areas of Hematology and Diabetes

● Life Sciences services provide specialist manufacture of enzymes and custom products for use in diagnostic, food and industrial applications.

EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.